Primary Androgen Deprivation Therapy Hikes Diabetes Risk

Share this content:
Primary Androgen Deprivation Therapy Hikes Diabetes Risk
Primary Androgen Deprivation Therapy Hikes Diabetes Risk

(HealthDay News) — Primary androgen deprivation therapy increases diabetes risk, particularly in men aged younger than 70 years, according to research published in The Journal of Urology.

Huei-Ting Tsai, PhD, from the Georgetown University Medical Center in Washington, D.C., and colleagues analyzed retrospective data from 12,191 men diagnosed with incident localized prostate cancer from 1995 to 2008 (age 35 to 100 years). 

The men were without diabetes at diagnosis and did not receive prostatectomy or radiation. Primary androgen deprivation therapy was characterized as occurring within 1 year of diagnosis.

Over a median 4.8 years of follow up, 9.9% of patients developed diabetes, results indicated. The respective incidence rates were 2.5 and 1.6 events per 100 person-years in the primary androgen deprivation therapy and nonprimary androgen deprivation therapy groups. 

The researchers also found that there was a 1.61-fold increase in diabetes risk with primary androgen deprivation therapy. The number needed to harm was 29. In men aged 70 years and younger, the association was stronger, compared with older men (HR=2.25 vs. 1.40; P=.008).

"Primary androgen deprivation therapy may increase diabetes risk by 60% and should be used with caution when managing localized prostate cancer," the researchers wrote. 

"Because of the consistent association between androgen deprivation therapy and greater diabetes risk across disease states, we recommend routine screening and lifestyle interventions to reduce the risk of diabetes in men receiving androgen deprivation therapy."

Reference

  1. Tsai H-T et al. J Urol. 2015;193(6):1956-1962.
You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus